209 related articles for article (PubMed ID: 27272846)
21. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
Friedman E; Kotsopoulos J; Lubinski J; Lynch HT; Ghadirian P; Neuhausen SL; Isaacs C; Weber B; Foulkes WD; Moller P; Rosen B; Kim-Sing C; Gershoni-Baruch R; Ainsworth P; Daly M; Tung N; Eisen A; Olopade OI; Karlan B; Saal HM; Garber JE; Rennert G; Gilchrist D; Eng C; Offit K; Osborne M; Sun P; Narod SA;
Breast Cancer Res; 2006; 8(2):R15. PubMed ID: 16563180
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
23. [Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations].
Pericay C; Díez O; Campos B; Balmaña J; Domènech M; Lerma E; Baena M; Maria Sabaté J; Gómez A; José López J; Baiget M; Alonso C
Med Clin (Barc); 2001 Jul; 117(5):161-6. PubMed ID: 11481082
[TBL] [Abstract][Full Text] [Related]
24. Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
Nisman B; Allweis TM; Carmon E; Kadouri L; Maly B; Maimon O; Meierovich A; Peretz T
Anticancer Res; 2020 Nov; 40(11):6417-6428. PubMed ID: 33109580
[TBL] [Abstract][Full Text] [Related]
25. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
[TBL] [Abstract][Full Text] [Related]
28. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
29. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Hartman AR; Kaldate RR; Sailer LM; Painter L; Grier CE; Endsley RR; Griffin M; Hamilton SA; Frye CA; Silberman MA; Wenstrup RJ; Sandbach JF
Cancer; 2012 Jun; 118(11):2787-95. PubMed ID: 22614657
[TBL] [Abstract][Full Text] [Related]
31. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
de la Hoya M; Fernández JM; Tosar A; Godino J; Sánchez de Abajo A; Vidart JA; Pérez-Segura P; Díaz-Rubio E; Caldés T
JAMA; 2003 Aug; 290(7):929-31. PubMed ID: 12928470
[TBL] [Abstract][Full Text] [Related]
32. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
33. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Tea MK; Kroiss R; Muhr D; Fuerhauser-Rappaport C; Oefner P; Wagner TM; Singer CF
Maturitas; 2014 Jan; 77(1):68-72. PubMed ID: 24156927
[TBL] [Abstract][Full Text] [Related]
34. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
37. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
38. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Couch FJ; Sinilnikova O; Vierkant RA; Pankratz VS; Fredericksen ZS; Stoppa-Lyonnet D; Coupier I; Hughes D; Hardouin A; Berthet P; Peock S; Cook M; Baynes C; Hodgson S; Morrison PJ; Porteous ME; Jakubowska A; Lubinski J; Gronwald J; Spurdle AB; ; Schmutzler R; Versmold B; Engel C; Meindl A; Sutter C; Horst J; Schaefer D; Offit K; Kirchhoff T; Andrulis IL; Ilyushik E; Glendon G; Devilee P; Vreeswijk MP; Vasen HF; Borg A; Backenhorn K; Struewing JP; Greene MH; Neuhausen SL; Rebbeck TR; Nathanson K; Domchek S; Wagner T; Garber JE; Szabo C; Zikan M; Foretova L; Olson JE; Sellers TA; Lindor N; Nevanlinna H; Tommiska J; Aittomaki K; Hamann U; Rashid MU; Torres D; Simard J; Durocher F; Guenard F; Lynch HT; Isaacs C; Weitzel J; Olopade OI; Narod S; Daly MB; Godwin AK; Tomlinson G; Easton DF; Chenevix-Trench G; Antoniou AC;
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1416-21. PubMed ID: 17627006
[TBL] [Abstract][Full Text] [Related]
39. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
40. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
